Economy1 Narrative Timeline Events
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Merck.com See more headlines & perspectives on Google News
Narrative Evolution & Timeline
Trace how this story developed across dispatches and source updates.
Story Begins
The first development in this ongoing narrative has been documented.
Discussion (0)